Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease

Inclusion Criteria: * Age ≥ 18 years * eGFR ≥20 and \<90 mL/min/1.73m2 * Urinary albumin to creatinine ratio \>30 mg/g and \<3500 mg/g * BMI \>21 kg/m2 * Stable kidney function (no more than 30% change in eGFR in the 3 months prior to enrolment) * On a stable maximum tolerated dose of an ACEi/ARB for at least 4 weeks prior to enrolment * If using an SGLT2 inhibitor, receiving a stable dose for at least 8 weeks prior to enrolment * Willing to sign an informed consent Exclusion Criteria: * Diagnosis of type 1 diabetes * Cardiovascular event within 3 months prior to enrolment * Treatment with GLP-1RA for \<12 weeks prior to screening * Evidence of severe hepatic impairment determined by any one of: ALT or AST values exceeding 3x ULN, a history of hepatic encephalopathy, a history of oesophageal varices, or a history of portocaval shunt; * Active pregnancy or breastfeeding * History of kidney or liver transplant * Active malignancy * Suggestive evidence of adrenal insufficiency * Acute pancreatitis \<180 days prior to screening * History of chronic pancreatitis or idiopathic acute pancreatitisPersonal or family history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma * Calcitonin levels ≥100 pg/mL or 29.26 pmol/L * Personal history of non-familial medullary thyroid carcinoma * History of severe hypersensitivity or contraindications to any glucagon RA or GLP-1 RA * Uncontrolled arterial hypertension (mean semi supine systolic blood pressure …